Cybrexa has secured $25m to progress a cancer treatment based on research at Yale University and University of Rhode Island.
Cybrexa Therapeutics, a US-based oncology therapy developer exploiting Yale University and University of Rhode Island research, closed a $25m series B round yesterday featuring HighCape Capital and Elm Street Ventures.
Cybrexa is working on a platform that enables an antigen-independent targeting of tumours and intracellular delivery of cancer treatments.
The capital will allow Cybrexa to move its lead asset, CBX-12, into phase 1/2 trials in the first half of this year. The programme is aimed at advanced solid tumours.
Kevin…
